Ladenburg Thalmann Upgrades Aileron Therapeutics to Buy, Announces $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov has upgraded Aileron Therapeutics (NASDAQ:ALRN) from Neutral to Buy and set a price target of $9.
December 01, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aileron Therapeutics was upgraded from Neutral to Buy by Ladenburg Thalmann, with a new price target of $9.
Upgrades by analysts typically lead to a positive short term reaction in the stock price as they suggest a better outlook for the company. The new price target of $9 indicates a significant upside potential from the current trading price, assuming the stock was trading below this target prior to the upgrade.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100